英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
merke查看　merke　在百度字典中的解释百度英翻中〔查看〕
merke查看　merke　在Google字典中的解释Google英翻中〔查看〕
merke查看　merke　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Merck | Home
    At Merck, we're following the science to tackle some of the world's greatest health threats Get a glimpse of how we work to improve lives
  • Products list - Merck. com
    Products list The product websites presented here are intended for use in the United States, its territories and Puerto Rico only Other countries may have different regulatory requirements and review practices that may require referencing different information
  • Discover Job Opportunities at Merck | Merck Careers
    Explore current job opportunities at Merck Learn more about careers in Business Support, Clinical, Engineering, Information Technology, Research Development, Manufacturing and Marketing
  • Who we are - Merck. com
    Merck aspires to be the premier research-intensive biopharmaceutical company in the world Learn about our commitment to save and improve lives
  • History - Merck. com
    Learn how Merck has created a legacy of inventing medicines and vaccines and become a leading global biopharmaceutical company over the past 130 years
  • Merck Announces First-Quarter 2025 Financial Results
    RAHWAY, N J --(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025 “Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Robert M Davis, chairman and chief
  • Investor relations - Merck. com
    Innovation Our Q4 and full-year 2024 financial results Merck’s (NYSE: MRK) Q4 and full-year 2024 results reflect strong growth Our company announced Q4 worldwide sales of $15 6 billion, an increase of 7% from Q4 2023
  • Discover our Sales openings | Merck Careers
    Discover Sales job opportunities at Merck Apply to a Sales job opportunity at Merck
  • What can we help you find? - Merck
    Study also met secondary endpoint of overall survival (OS) for patients whose tumors express PD-L1 KEYTRUDA® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first immune checkpoint inhibitor-based regimen to show a statistically significant improvement in OS for ovarian cancer Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today
  • Merck Enters into Exclusive Global License Agreement with Hansoh Pharma . . .
    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist “We continue to leverage science-driven business development to augment and complement our





中文字典-英文字典  2005-2009